Blonder Tongue Laboratories Inc (BDR) Fundamental Analysis & Valuation

NYSEARCA:BDR • US0936981085

Current stock price

0.305
+0 (+1.46%)
At close:
0.305
0 (0%)
After Hours:

This BDR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BDR Profitability Analysis

1.1 Basic Checks

  • In the past year BDR has reported negative net income.
BDR Yearly Net Income VS EBIT VS OCF VS FCFBDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA -5.64%
ROE 2.56%
ROIC -40.64%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDR Yearly ROA, ROE, ROICBDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 -200 -400 -600

1.3 Margins

Industry RankSector Rank
OM -19.82%
PM (TTM) -4.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDR Yearly Profit, Operating, Gross MarginsBDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. BDR Health Analysis

2.1 Basic Checks

  • BDR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for BDR has been increased compared to 1 year ago.
  • The debt/assets ratio for BDR has been reduced compared to a year ago.
BDR Yearly Shares OutstandingBDR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
BDR Yearly Total Debt VS Total AssetsBDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 5M 10M 15M

2.2 Solvency

  • BDR has an Altman-Z score of -1.77. This is a bad value and indicates that BDR is not financially healthy and even has some risk of bankruptcy.
  • BDR has a Debt/Equity ratio of 0.64. This is a neutral value indicating BDR is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -1.77
ROIC/WACC-2.89
WACC14.05%
BDR Yearly LT Debt VS Equity VS FCFBDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 5M -5M

2.3 Liquidity

  • BDR has a Current Ratio of 1.11. This is a normal value and indicates that BDR is financially healthy and should not expect problems in meeting its short term obligations.
  • BDR has a Quick Ratio of 1.11. This is a bad value and indicates that BDR is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.38
BDR Yearly Current Assets VS Current LiabilitesBDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BDR Growth Analysis

3.1 Past

  • BDR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.82%, which is quite impressive.
  • The Revenue has been growing slightly by 1.67% in the past year.
  • Measured over the past years, BDR shows a decrease in Revenue. The Revenue has been decreasing by -6.89% on average per year.
EPS 1Y (TTM)87.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.47%
Revenue 1Y (TTM)1.67%
Revenue growth 3Y-10.15%
Revenue growth 5Y-6.89%
Sales Q2Q%2.74%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDR Yearly Revenue VS EstimatesBDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

0

4. BDR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BDR. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDR Price Earnings VS Forward Price EarningsBDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.98
BDR Per share dataBDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDR Dividend Analysis

5.1 Amount

  • No dividends for BDR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BDR Fundamentals: All Metrics, Ratios and Statistics

Blonder Tongue Laboratories Inc

NYSEARCA:BDR (6/24/2022, 8:26:09 PM)

After market: 0.305 0 (0%)

0.305

+0 (+1.46%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)05-06
Earnings (Next)N/A
Inst Owners1.05%
Inst Owner Change0%
Ins Owners46.47%
Ins Owner Change0%
Market Cap4.06M
Revenue(TTM)15.84M
Net Income(TTM)-650.00K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB N/A
EV/EBITDA -1.98
EPS(TTM)-0.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.19
BVpS0.18
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.64%
ROE 2.56%
ROCE N/A
ROIC -40.64%
ROICexc N/A
ROICexgc -49.44%
OM -19.82%
PM (TTM) -4.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.37
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.38
Altman-Z -1.77
F-Score3
WACC14.05%
ROIC/WACC-2.89
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.67%
Revenue growth 3Y-10.15%
Revenue growth 5Y-6.89%
Sales Q2Q%2.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Blonder Tongue Laboratories Inc / BDR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Blonder Tongue Laboratories Inc (BDR) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BDR.


What is the valuation status for BDR stock?

ChartMill assigns a valuation rating of 1 / 10 to Blonder Tongue Laboratories Inc (BDR). This can be considered as Overvalued.


What is the profitability of BDR stock?

Blonder Tongue Laboratories Inc (BDR) has a profitability rating of 1 / 10.